Exelixis (EXEL) vs. BMRN and NBIX: Can CABOMETYX and Pipeline Growth Revive Investor Confidence?

insidermonkey.com · 2026-10-29

Is EXEL a good stock to buy? We came across a bullish thesis on Exelixis, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on EXEL.

TickrTrends take: Exelixis trades at a fairly valued level according to TickrTrends metrics, suggesting the market has already priced in reasonable expectations for the company's performance in the Healthcare sector. Investors monitoring this stock should watch whether CABOMETYX revenue trends and pipeline advancement can demonstrate growth rates that justify maintaining this valuation or whether execution gaps could shift the assessment. The comparison to competitors BMRN and NBIX provides context for evaluating whether EXEL's growth prospects are competitive enough to sustain current pricing or face valuation pressure.

Read the full story at insidermonkey.com →